Julie Sweetland, PhD, shares strategies to improve vaccine conversations by explaining the science, acknowledging parental concerns, and building trust.
News|Videos|October 1, 2022
How to prepare for this upcoming flu season
Author(s)Morgan Ebert, Executive Editor
Gregg Sylvester, MD, MPH, chief health officer at CSL Seqirus, discusses an FDA-approved cell-based flu vaccine for children as young as 6 months, trends in childhood vaccination rates, and how to prepare for the upcoming flu season.
Advertisement
Advertisement
Related to this article
CDC confirmed the first pediatric flu death of 2026-27, linked to H1N1, as early flu activity rises in 2026.
A Contemporary Pediatrics Peer Exchange panel reviews RSV risk, testing, maternal vaccination, and long-acting monoclonal antibodies, and where infants still slip through the cracks.
Completing the DTaP primary series was 96.2% effective against pertussis in Alaska children aged 6 months to 6 years during a record 2024 outbreak.
CDC data show pediatric CP-CRE incidence rose 92% from 2019 to 2024, driven by NDM-CRE, mostly in children with complex medical needs.
A meta-analysis of 7 real-world studies found maternal RSVpreF 78% effective against RSV LRTI hospitalization in infants up to 6 months.
New real-world data reveal delays and disparities in nirsevimab administration, highlighting opportunities to improve timely RSV protection for infants.
With California WNV activity at a 5-year high, CHLA outlines age-based repellent and bite-prevention guidance for children.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
How pediatricians can reframe vaccine conversations
2
FDA investigates malignancy risk with SMA gene therapy Zolgensma
3
Distance to surgery linked to complications, longer stays in children
4
Risankizumab shows 52-week efficacy in pediatric psoriasis trial
5